Results 171 to 180 of about 2,740,548 (363)
Rare Dysfunctional Complement Factor I Genetic Variants and Progression to Advanced Age-Related Macular Degeneration. [PDF]
Ophthalmol Sci, 2023 Seddon JM +5 more
europepmc +1 more source
Molecular Oncology, EarlyView.Comprehensive cancer centre (CCCs) and CCCs of Excellence (CCCoE) integration in healthcare. Through outreach to surrounding community hospitals, CCCs enable wider access to top‐clinical cancer treatments and care, thereby facilitating the swift enrolment of patients into data‐rich clinical trials (PI‐initiated trials testing new concepts, drug ...
Anton Berns +4 more
wiley +1 more source
Scientific ReportsThe immediate defense provided by the alternative complement pathway (AP) is under constant control by fluid phase regulators, factor H (FH) and factor I (FI), to prevent nonessential activation.
Nancy A. Turner, Joel L. Moake
doaj +1 more source
The Optimal Approximation Factor in Density Estimation [PDF]
arXiv, 2019 Consider the following problem: given two arbitrary densities $q_1,q_2$ and a sample-access to an unknown target density $p$, find which of the $q_i$'s is closer to $p$ in total variation. A remarkable result due to Yatracos shows that this problem is tractable in the following sense: there exists an algorithm that uses $O(\epsilon^{-2})$ samples ...
arxiv
Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma
Molecular Oncology, EarlyView.GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski +19 more
wiley +1 more source
Ontogeny of Complement Regulatory Proteins – Concentrations of Factor H, Factor I, C4b‐Binding Protein, Properdin and Vitronectin in Healthy Children of Different Ages and in Adults [PDF]
, 2003 P. Ferreira de Paula +6 more
openalex +1 more source
Pearls & Oy-sters: Homozygous Complement Factor I Deficiency Presenting as Fulminant Relapsing Complement-Mediated CNS Vasculitis. [PDF]
Neurology, 2023 Levit E, Leon J, Lincoln MR.
europepmc +1 more source
Molecular Oncology, EarlyView.C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald +18 more
wiley +1 more source
Molecular Oncology, EarlyView.Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley +1 more source
Inference in matrix-valued time series with common stochastic trends and multifactor error structure [PDF]
arXivWe develop an estimation methodology for a factor model for high-dimensional matrix-valued time series, where common stochastic trends and common stationary factors can be present. We study, in particular, the estimation of (row and column) loading spaces, of the common stochastic trends and of the common stationary factors, and the row and column ...
arxiv